Alternative LDL Cholesterol safely and effectively lowers risk of ASCVD instead of high intensity statins: JAMA

For high-risk patients with atherosclerotic cardiovascular disease (ASCVD), intensive lowering of low-density lipoprotein (LDL) cholesterol levels is advised. High-intensity statins are the recommended first-line treatment for such conditions. However, high-intensity statins can have some side effects and lead to poor long-term adherence. The previous literature suggested a combination of moderate-intensity statin with LDL cholesterol-lowering drugs to reduce the side effects and improve tolerance. Most of the previous research has explored the impact of such a combination on preventing adverse cardiovascular events. As there is limited research on the effects of LDL cholesterol-lowering drugs on effectiveness and safety, researchers conducted a systematic review and meta-analysis on the long-term efficacy and safety of an alternative LDL cholesterol–lowering strategy vs. high-intensity statin strategy in patients with ASCVD in randomized clinical trials. 

A literature search was carried out from databases like PubMed, Embase, and other websites (ClinicalTrials.gov, European Society of Cardiology, tctMD) to include randomized clinical trials comparing an alternative LDL cholesterol–lowering strategy vs. a high-intensity statin strategy in patients with ASCVD, with the presence of cardiovascular events as endpoints. Many studies were filtered, and two trials were deemed eligible. They were the RACING trial and the LODESTAR trial. The moderate-intensity statin with ezetimibe combination therapy in the RACING trial and the treat-to-target strategy in the LODESTAR trial were classified as alternative LDL cholesterol-lowering strategies. The primary endpoint was to assess a 3-year composite of all-cause death, myocardial infarction, stroke, or coronary revascularization, while the secondary endpoints comprised clinical efficacy and safety endpoints.